<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23924316</PMID><DateCompleted><Year>2014</Year><Month>01</Month><Day>23</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2180</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2013</Year><Month>Aug</Month><Day>07</Day></PubDate></JournalIssue><Title>BMC microbiology</Title><ISOAbbreviation>BMC Microbiol</ISOAbbreviation></Journal><ArticleTitle>Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry.</ArticleTitle><Pagination><StartPage>187</StartPage><MedlinePgn>187</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1471-2180-13-187</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">We previously identified two hydrolyzable tannins, chebulagic acid (CHLA) and punicalagin (PUG) that blocked herpes simplex virus type 1 (HSV-1) entry and spread. These compounds inhibited viral glycoprotein interactions with cell surface glycosaminoglycans (GAGs). Based on this property, we evaluated their antiviral efficacy against several different viruses known to employ GAGs for host cell entry.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Extensive analysis of the tannins' mechanism of action was performed on a panel of viruses during the attachment and entry steps of infection. Virus-specific binding assays and the analysis of viral spread during treatment with these compounds were also conducted. CHLA and PUG were effective in abrogating infection by human cytomegalovirus (HCMV), hepatitis C virus (HCV), dengue virus (DENV), measles virus (MV), and respiratory syncytial virus (RSV), at &#x3bc;M concentrations and in dose-dependent manners without significant cytotoxicity. Moreover, the natural compounds inhibited viral attachment, penetration, and spread, to different degrees for each virus. Specifically, the tannins blocked all these steps of infection for HCMV, HCV, and MV, but had little effect on the post-fusion spread of DENV and RSV, which could suggest intriguing differences in the roles of GAG-interactions for these viruses.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">CHLA and PUG may be of value as broad-spectrum antivirals for limiting emerging/recurring viruses known to engage host cell GAGs for entry. Further studies testing the efficacy of these tannins in vivo against certain viruses are justified.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Liang-Tzung</ForeName><Initials>LT</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ting-Ying</ForeName><Initials>TY</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Song-Chow</ForeName><Initials>SC</Initials></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Chueh-Yao</ForeName><Initials>CY</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Ta-Chen</ForeName><Initials>TC</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Guey-Horng</ForeName><Initials>GH</Initials></Author><Author ValidYN="Y"><LastName>Anderson</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Chun-Ching</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>Richardson</LastName><ForeName>Christopher D</ForeName><Initials>CD</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MOP-10638</GrantID><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant><Grant><GrantID>MOP-114949</GrantID><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>08</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Microbiol</MedlineTA><NlmUniqueID>100966981</NlmUniqueID><ISSNLinking>1471-2180</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001578">Benzopyrans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005960">Glucosides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006025">Glycosaminoglycans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047348">Hydrolyzable Tannins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011991">Receptors, Virus</NameOfSubstance></Chemical><Chemical><RegistryNumber>23094-71-5</RegistryNumber><NameOfSubstance UI="C076178">chebulagic acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>65995-63-3</RegistryNumber><NameOfSubstance UI="C115642">punicalagin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001578" MajorTopicYN="N">Benzopyrans</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005960" MajorTopicYN="N">Glucosides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006025" MajorTopicYN="N">Glycosaminoglycans</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047348" MajorTopicYN="N">Hydrolyzable Tannins</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011991" MajorTopicYN="N">Receptors, Virus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014777" MajorTopicYN="N">Virus Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053586" MajorTopicYN="N">Virus Internalization</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018406" MajorTopicYN="N">Virus Physiological Phenomena</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014780" MajorTopicYN="N">Viruses</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23924316</ArticleId><ArticleId IdType="pmc">PMC3750913</ArticleId><ArticleId IdType="doi">10.1186/1471-2180-13-187</ArticleId><ArticleId IdType="pii">1471-2180-13-187</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rothman AL. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol. 2011;11(8):532&#x2013;543. doi: 10.1038/nri3014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3014</ArticleId><ArticleId IdType="pubmed">21760609</ArticleId></ArticleIdList></Reference><Reference><Citation>Torresi J, Johnson D, Wedemeyer H. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J Hepatol. 2011;54(6):1273&#x2013;1285. doi: 10.1016/j.jhep.2010.09.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2010.09.040</ArticleId><ArticleId IdType="pubmed">21236312</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung H, Schleiss MR. Update on the current status of cytomegalovirus vaccines. Expert Rev Vaccines. 2010;9(11):1303&#x2013;1314. doi: 10.1586/erv.10.125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/erv.10.125</ArticleId><ArticleId IdType="pmc">PMC3595507</ArticleId><ArticleId IdType="pubmed">21087108</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright M, Piedimonte G. Respiratory syncytial virus prevention and therapy: past, present, and future. Pediatr Pulmonol. 2011;46(4):324&#x2013;347. doi: 10.1002/ppul.21377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ppul.21377</ArticleId><ArticleId IdType="pubmed">21438168</ArticleId></ArticleIdList></Reference><Reference><Citation>Munier CM, Andersen CR, Kelleher AD. HIV vaccines: progress to date. Drugs. 2011;71(4):387&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">21395355</ArticleId></ArticleIdList></Reference><Reference><Citation>Heeney JL. Zoonotic viral diseases and the frontier of early diagnosis, control and prevention. J Intern Med. 2006;260(5):399&#x2013;408. doi: 10.1111/j.1365-2796.2006.01711.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2796.2006.01711.x</ArticleId><ArticleId IdType="pubmed">17040245</ArticleId></ArticleIdList></Reference><Reference><Citation>Christou L. The global burden of bacterial and viral zoonotic infections. Clin Microbiol Infect. 2011;17(3):326&#x2013;330. doi: 10.1111/j.1469-0691.2010.03441.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-0691.2010.03441.x</ArticleId><ArticleId IdType="pmc">PMC7129620</ArticleId><ArticleId IdType="pubmed">21129102</ArticleId></ArticleIdList></Reference><Reference><Citation>Cascio A, Bosilkovski M, Rodriguez-Morales AJ, Pappas G. The socio-ecology of zoonotic infections. Clin Microbiol Infect. 2011;17(3):336&#x2013;342. doi: 10.1111/j.1469-0691.2010.03451.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-0691.2010.03451.x</ArticleId><ArticleId IdType="pubmed">21175957</ArticleId></ArticleIdList></Reference><Reference><Citation>Grais RF, Strebel P, Mala P, Watson J, Nandy R, Gayer M. Measles vaccination in humanitarian emergencies: a review of recent practice. Confl Health. 2011;5(1):21. doi: 10.1186/1752-1505-5-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1752-1505-5-21</ArticleId><ArticleId IdType="pmc">PMC3195113</ArticleId><ArticleId IdType="pubmed">21942984</ArticleId></ArticleIdList></Reference><Reference><Citation>Arduino PG, Porter SR. Oral and perioral herpes simplex virus type 1 (HSV-1) infection: review of its management. Oral diseases. 2006;12(3):254&#x2013;270. doi: 10.1111/j.1601-0825.2006.01202.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1601-0825.2006.01202.x</ArticleId><ArticleId IdType="pubmed">16700734</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano V, Vispo E, Poveda E, Labarga P, Martin-Carbonero L, Fernandez-Montero JV, Barreiro P. Directly acting antivirals against hepatitis C virus. J Antimicrob Chemother. 2011;66(8):1673&#x2013;1686. doi: 10.1093/jac/dkr215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkr215</ArticleId><ArticleId IdType="pubmed">21652618</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitrasinovic PM. Advances in the structure-based design of the influenza A neuraminidase inhibitors. Curr Drug Targets. 2010;11(3):315&#x2013;326. doi: 10.2174/138945010790711932.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138945010790711932</ArticleId><ArticleId IdType="pubmed">20210756</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawlotsky JM. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology. 2011;53(5):1742&#x2013;1751. doi: 10.1002/hep.24262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.24262</ArticleId><ArticleId IdType="pubmed">21374691</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh RK, Ghosh SM, Chawla S. Recent advances in antiretroviral drugs. Expert Opin Pharmacother. 2011;12(1):31&#x2013;46. doi: 10.1517/14656566.2010.509345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14656566.2010.509345</ArticleId><ArticleId IdType="pubmed">20698725</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergman SJ, Ferguson MC, Santanello C. Interferons as therapeutic agents for infectious diseases. Infect Dis Clin North Am. 2011;25(4):819&#x2013;834. doi: 10.1016/j.idc.2011.07.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idc.2011.07.008</ArticleId><ArticleId IdType="pmc">PMC7134994</ArticleId><ArticleId IdType="pubmed">22054758</ArticleId></ArticleIdList></Reference><Reference><Citation>Bekisz J, Schmeisser H, Hernandez J, Goldman ND, Zoon KC. Human interferons alpha, beta and omega. Growth Factors. 2004;22(4):243&#x2013;251. doi: 10.1080/08977190400000833.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08977190400000833</ArticleId><ArticleId IdType="pubmed">15621727</ArticleId></ArticleIdList></Reference><Reference><Citation>Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M, Shiffman ML, Yurdaydin C, Dalgard O. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol. 2011;8(4):212&#x2013;223. doi: 10.1038/nrgastro.2011.21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2011.21</ArticleId><ArticleId IdType="pubmed">21386812</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi NS, Mancera RL. The structure of glycosaminoglycans and their interactions with proteins. Chem Biol Drug Des. 2008;72(6):455&#x2013;482. doi: 10.1111/j.1747-0285.2008.00741.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1747-0285.2008.00741.x</ArticleId><ArticleId IdType="pubmed">19090915</ArticleId></ArticleIdList></Reference><Reference><Citation>Bishop JR, Schuksz M, Esko JD. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature. 2007;446(7139):1030&#x2013;1037. doi: 10.1038/nature05817.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature05817</ArticleId><ArticleId IdType="pubmed">17460664</ArticleId></ArticleIdList></Reference><Reference><Citation>Germi R, Crance JM, Garin D, Guimet J, Lortat-Jacob H, Ruigrok RW, Zarski JP, Drouet E. Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption. J Med Virol. 2002;68(2):206&#x2013;215. doi: 10.1002/jmv.10196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.10196</ArticleId><ArticleId IdType="pubmed">12210409</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth H, Schafer C, Adah MI, Zhang F, Linhardt RJ, Toyoda H, Kinoshita-Toyoda A, Toida T, Van Kuppevelt TH, Depla E. et al.Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem. 2003;278(42):41003&#x2013;41012. doi: 10.1074/jbc.M302267200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M302267200</ArticleId><ArticleId IdType="pubmed">12867431</ArticleId></ArticleIdList></Reference><Reference><Citation>Banfield BW, Leduc Y, Esford L, Schubert K, Tufaro F. Sequential isolation of proteoglycan synthesis mutants by using herpes simplex virus as a selective agent: evidence for a proteoglycan-independent virus entry pathway. J Virol. 1995;69(6):3290&#x2013;3298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC189040</ArticleId><ArticleId IdType="pubmed">7745676</ArticleId></ArticleIdList></Reference><Reference><Citation>Shieh MT, WuDunn D, Montgomery RI, Esko JD, Spear PG. Cell surface receptors for herpes simplex virus are heparan sulfate proteoglycans. J Cell Biol. 1992;116(5):1273&#x2013;1281. doi: 10.1083/jcb.116.5.1273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.116.5.1273</ArticleId><ArticleId IdType="pmc">PMC2289355</ArticleId><ArticleId IdType="pubmed">1310996</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman SA, Audet S, Beeler JA. The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate. J Virol. 2000;74(14):6442&#x2013;6447. doi: 10.1128/JVI.74.14.6442-6447.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.74.14.6442-6447.2000</ArticleId><ArticleId IdType="pmc">PMC112152</ArticleId><ArticleId IdType="pubmed">10864656</ArticleId></ArticleIdList></Reference><Reference><Citation>Terao-Muto Y, Yoneda M, Seki T, Watanabe A, Tsukiyama-Kohara K, Fujita K, Kai C. Heparin-like glycosaminoglycans prevent the infection of measles virus in SLAM-negative cell lines. Antiviral Res. 2008;80(3):370&#x2013;376. doi: 10.1016/j.antiviral.2008.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2008.08.006</ArticleId><ArticleId IdType="pubmed">18812191</ArticleId></ArticleIdList></Reference><Reference><Citation>Compton T, Nowlin DM, Cooper NR. Initiation of human cytomegalovirus infection requires initial interaction with cell surface heparan sulfate. Virology. 1993;193(2):834&#x2013;841. doi: 10.1006/viro.1993.1192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.1993.1192</ArticleId><ArticleId IdType="pubmed">8384757</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilgard P, Stockert R. Heparan sulfate proteoglycans initiate dengue virus infection of hepatocytes. Hepatology. 2000;32(5):1069&#x2013;1077. doi: 10.1053/jhep.2000.18713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/jhep.2000.18713</ArticleId><ArticleId IdType="pubmed">11050058</ArticleId></ArticleIdList></Reference><Reference><Citation>Barth H, Schnober EK, Zhang F, Linhardt RJ, Depla E, Boson B, Cosset FL, Patel AH, Blum HE, Baumert TF. Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J Virol. 2006;80(21):10579&#x2013;10590. doi: 10.1128/JVI.00941-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00941-06</ArticleId><ArticleId IdType="pmc">PMC1641783</ArticleId><ArticleId IdType="pubmed">16928753</ArticleId></ArticleIdList></Reference><Reference><Citation>Koutsoudakis G, Kaul A, Steinmann E, Kallis S, Lohmann V, Pietschmann T, Bartenschlager R. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol. 2006;80(11):5308&#x2013;5320. doi: 10.1128/JVI.02460-05.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02460-05</ArticleId><ArticleId IdType="pmc">PMC1472176</ArticleId><ArticleId IdType="pubmed">16699011</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Hatziioannou T, Zang T, Braaten D, Luban J, Goff SP, Bieniasz PD. Envelope-dependent, cyclophilin-independent effects of glycosaminoglycans on human immunodeficiency virus type 1 attachment and infection. J Virol. 2002;76(12):6332&#x2013;6343. doi: 10.1128/JVI.76.12.6332-6343.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.76.12.6332-6343.2002</ArticleId><ArticleId IdType="pmc">PMC136233</ArticleId><ArticleId IdType="pubmed">12021366</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng MN, Whitehead SS, Collins PL. Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. Virology. 2001;289(2):283&#x2013;296. doi: 10.1006/viro.2001.1138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.2001.1138</ArticleId><ArticleId IdType="pubmed">11689051</ArticleId></ArticleIdList></Reference><Reference><Citation>Crim RL, Audet SA, Feldman SA, Mostowski HS, Beeler JA. Identification of linear heparin-binding peptides derived from human respiratory syncytial virus fusion glycoprotein that inhibit infectivity. J Virol. 2007;81(1):261&#x2013;271. doi: 10.1128/JVI.01226-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01226-06</ArticleId><ArticleId IdType="pmc">PMC1797247</ArticleId><ArticleId IdType="pubmed">17050595</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin LT, Chen TY, Chung CY, Noyce RS, Grindley TB, McCormick C, Lin TC, Wang GH, Lin CC, Richardson CD. Hydrolyzable tannins (chebulagic acid and punicalagin) target viral glycoprotein-glycosaminoglycan interactions to inhibit herpes simplex virus 1 entry and cell-to-cell spread. J Virol. 2011;85(9):4386&#x2013;4398. doi: 10.1128/JVI.01492-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01492-10</ArticleId><ArticleId IdType="pmc">PMC3126266</ArticleId><ArticleId IdType="pubmed">21307190</ArticleId></ArticleIdList></Reference><Reference><Citation>Julander JG, Perry ST, Shresta S. Important advances in the field of anti-dengue virus research. Antivir Chem Chemother. 2011;21(3):105&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">21233532</ArticleId></ArticleIdList></Reference><Reference><Citation>Prichard MN, Kern ER. The search for new therapies for human cytomegalovirus infections. Virus Res. 2011;157(2):212&#x2013;221. doi: 10.1016/j.virusres.2010.11.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2010.11.004</ArticleId><ArticleId IdType="pmc">PMC3068221</ArticleId><ArticleId IdType="pubmed">21095209</ArticleId></ArticleIdList></Reference><Reference><Citation>Plemper RK, Snyder JP. Measles control&#x2013;can measles virus inhibitors make a difference? Curr Opin Investig Drugs. 2009;10(8):811&#x2013;820.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2728049</ArticleId><ArticleId IdType="pubmed">19649926</ArticleId></ArticleIdList></Reference><Reference><Citation>Ono N, Tatsuo H, Hidaka Y, Aoki T, Minagawa H, Yanagi Y. Measles viruses on throat swabs from measles patients use signaling lymphocytic activation molecule (CDw150) but not CD46 as a cellular receptor. J Virol. 2001;75(9):4399&#x2013;4401. doi: 10.1128/JVI.75.9.4399-4401.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.75.9.4399-4401.2001</ArticleId><ArticleId IdType="pmc">PMC114185</ArticleId><ArticleId IdType="pubmed">11287589</ArticleId></ArticleIdList></Reference><Reference><Citation>Welstead GG. &#x2018;The interaction between measles virus and its receptor. SLAM&#x2019;. Dissertation: University of Toronto; 2006.</Citation></Reference><Reference><Citation>Isaacson MK, Compton T. Human cytomegalovirus glycoprotein B is required for virus entry and cell-to-cell spread but not for virion attachment, assembly, or egress. J Virol. 2009;83(8):3891&#x2013;3903. doi: 10.1128/JVI.01251-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01251-08</ArticleId><ArticleId IdType="pmc">PMC2663263</ArticleId><ArticleId IdType="pubmed">19193805</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu EC, Hsi B, Hirota-Tsuchihara M, Ruland J, Iorio C, Sarangi F, Diao J, Migliaccio G, Tyrrell DL, Kneteman N. et al.Modified apoptotic molecule (BID) reduces hepatitis C virus infection in mice with chimeric human livers. Nat Biotechnol. 2003;21(5):519&#x2013;525. doi: 10.1038/nbt817.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt817</ArticleId><ArticleId IdType="pubmed">12704395</ArticleId></ArticleIdList></Reference><Reference><Citation>Marukian S, Jones CT, Andrus L, Evans MJ, Ritola KD, Charles ED, Rice CM, Dustin LB. Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology. 2008;48(6):1843&#x2013;1850. doi: 10.1002/hep.22550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.22550</ArticleId><ArticleId IdType="pmc">PMC2592497</ArticleId><ArticleId IdType="pubmed">19003912</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown MG, Huang YY, Marshall JS, King CA, Hoskin DW, Anderson R. Dramatic caspase-dependent apoptosis in antibody-enhanced dengue virus infection of human mast cells. J Leukoc Biol. 2009;85(1):71&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">18809735</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Cyr SL, Burt DS, Anderson R. Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine. J Clin Virol. 2009;44(4):287&#x2013;291. doi: 10.1016/j.jcv.2009.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2009.01.009</ArticleId><ArticleId IdType="pubmed">19233722</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonard VH, Sinn PL, Hodge G, Miest T, Devaux P, Oezguen N, Braun W, McCray PB Jr, McChesney MB, Cattaneo R. Measles virus blind to its epithelial cell receptor remains virulent in rhesus monkeys but cannot cross the airway epithelium and is not shed. J Clin Invest. 2008;118(7):2448&#x2013;2458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2430500</ArticleId><ArticleId IdType="pubmed">18568079</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercorelli B, Oreste P, Sinigalia E, Muratore G, Lembo D, Palu G, Loregian A. Sulfated derivatives of Escherichia coli K5 capsular polysaccharide are potent inhibitors of human cytomegalovirus. Antimicrob Agents Chemother. 2010;54(11):4561&#x2013;4567. doi: 10.1128/AAC.00721-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00721-10</ArticleId><ArticleId IdType="pmc">PMC2976136</ArticleId><ArticleId IdType="pubmed">20713657</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson CD, Scheid A, Choppin PW. Specific inhibition of paramyxovirus and myxovirus replication by oligopeptides with amino acid sequences similar to those at the N-termini of the F1 or HA2 viral polypeptides. Virology. 1980;105(1):205&#x2013;222. doi: 10.1016/0042-6822(80)90168-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0042-6822(80)90168-3</ArticleId><ArticleId IdType="pubmed">7414950</ArticleId></ArticleIdList></Reference><Reference><Citation>Sainz B Jr, Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, Marsh KA, Yu X, Chayama K, Alrefai WA. et al.Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med. 2012;18(2):281&#x2013;285. doi: 10.1038/nm.2581.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2581</ArticleId><ArticleId IdType="pmc">PMC3530957</ArticleId><ArticleId IdType="pubmed">22231557</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA. et al.Complete replication of hepatitis C virus in cell culture. Science. 2005;309(5734):623&#x2013;626. doi: 10.1126/science.1114016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1114016</ArticleId><ArticleId IdType="pubmed">15947137</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell RS, Meunier JC, Takikawa S, Faulk K, Engle RE, Bukh J, Purcell RH, Emerson SU. Advantages of a single-cycle production assay to study cell culture-adaptive mutations of hepatitis C virus. Proc Natl Acad Sci USA. 2008;105(11):4370&#x2013;4375. doi: 10.1073/pnas.0800422105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0800422105</ArticleId><ArticleId IdType="pmc">PMC2393785</ArticleId><ArticleId IdType="pubmed">18334634</ArticleId></ArticleIdList></Reference><Reference><Citation>Baba M, Snoeck R, Pauwels R, de Clercq E. Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus. Antimicrob Agents Chemother. 1988;32(11):1742&#x2013;1745. doi: 10.1128/AAC.32.11.1742.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.32.11.1742</ArticleId><ArticleId IdType="pmc">PMC175964</ArticleId><ArticleId IdType="pubmed">2472775</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayo-Puxan N, Cascallo M, Gros A, Huch M, Fillat C, Alemany R. Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting. J Gen Virol. 2006;87(Pt 9):2487&#x2013;2495.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894186</ArticleId></ArticleIdList></Reference><Reference><Citation>Dechecchi MC, Tamanini A, Bonizzato A, Cabrini G. Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions. Virology. 2000;268(2):382&#x2013;390. doi: 10.1006/viro.1999.0171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.1999.0171</ArticleId><ArticleId IdType="pubmed">10704346</ArticleId></ArticleIdList></Reference><Reference><Citation>Madan RP, Mesquita PM, Cheshenko N, Jing B, Shende V, Guzman E, Heald T, Keller MJ, Regen SL, Shattock RJ. et al.Molecular umbrellas: a novel class of candidate topical microbicides to prevent human immunodeficiency virus and herpes simplex virus infections. J Virol. 2007;81(14):7636&#x2013;7646. doi: 10.1128/JVI.02851-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02851-06</ArticleId><ArticleId IdType="pmc">PMC1933367</ArticleId><ArticleId IdType="pubmed">17494078</ArticleId></ArticleIdList></Reference><Reference><Citation>Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 2008;47(3):401&#x2013;409. doi: 10.1086/589862.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/589862</ArticleId><ArticleId IdType="pubmed">18558875</ArticleId></ArticleIdList></Reference><Reference><Citation>Fofana I, Krieger SE, Grunert F, Glauben S, Xiao F, Fafi-Kremer S, Soulier E, Royer C, Thumann C, Mee CJ. et al.Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology. 2010;139(3):953&#x2013;964. doi: 10.1053/j.gastro.2010.05.073. 964 e951-954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2010.05.073</ArticleId><ArticleId IdType="pubmed">20685314</ArticleId></ArticleIdList></Reference><Reference><Citation>Boltz DA, Aldridge JR Jr, Webster RG, Govorkova EA. Drugs in development for influenza. Drugs. 2010;70(11):1349&#x2013;1362. doi: 10.2165/11537960-000000000-00000.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11537960-000000000-00000</ArticleId><ArticleId IdType="pmc">PMC5558450</ArticleId><ArticleId IdType="pubmed">20614944</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf MC, Freiberg AN, Zhang T, Akyol-Ataman Z, Grock A, Hong PW, Li J, Watson NF, Fang AQ, Aguilar HC. et al.A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci USA. 2010;107(7):3157&#x2013;3162. doi: 10.1073/pnas.0909587107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0909587107</ArticleId><ArticleId IdType="pmc">PMC2840368</ArticleId><ArticleId IdType="pubmed">20133606</ArticleId></ArticleIdList></Reference><Reference><Citation>St Vincent MR, Colpitts CC, Ustinov AV, Muqadas M, Joyce MA, Barsby NL, Epand RF, Epand RM, Khramyshev SA, Valueva OA. et al.Rigid amphipathic fusion inhibitors, small molecule antiviral compounds against enveloped viruses. Proc Natl Acad Sci USA. 2010;107(40):17339&#x2013;17344. doi: 10.1073/pnas.1010026107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1010026107</ArticleId><ArticleId IdType="pmc">PMC2951442</ArticleId><ArticleId IdType="pubmed">20823220</ArticleId></ArticleIdList></Reference><Reference><Citation>Zasloff M, Adams AP, Beckerman B, Campbell A, Han Z, Luijten E, Meza I, Julander J, Mishra A, Qu W. et al.Squalamine as a broad-spectrum systemic antiviral agent with therapeutic potential. Proc Natl Acad Sci USA. 2011;108(38):15978&#x2013;15983. doi: 10.1073/pnas.1108558108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1108558108</ArticleId><ArticleId IdType="pmc">PMC3179074</ArticleId><ArticleId IdType="pubmed">21930925</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith EC, Popa A, Chang A, Masante C, Dutch RE. Viral entry mechanisms: the increasing diversity of paramyxovirus entry. Febs J. 2009;276(24):7217&#x2013;7227. doi: 10.1111/j.1742-4658.2009.07401.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-4658.2009.07401.x</ArticleId><ArticleId IdType="pmc">PMC2795005</ArticleId><ArticleId IdType="pubmed">19878307</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamb RA, Jardetzky TS. Structural basis of viral invasion: lessons from paramyxovirus F. Curr Opin Struct Biol. 2007;17(4):427&#x2013;436. doi: 10.1016/j.sbi.2007.08.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sbi.2007.08.016</ArticleId><ArticleId IdType="pmc">PMC2086805</ArticleId><ArticleId IdType="pubmed">17870467</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann B, Rossmann MG. Molecular mechanisms involved in the early steps of flavivirus cell entry. Microbes Infect. 2011;13(1):1&#x2013;9. doi: 10.1016/j.micinf.2010.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2010.09.005</ArticleId><ArticleId IdType="pmc">PMC3014442</ArticleId><ArticleId IdType="pubmed">20869460</ArticleId></ArticleIdList></Reference><Reference><Citation>Isaacson MK, Juckem LK, Compton T. Virus entry and innate immune activation. Curr Top Microbiol Immunol. 2008;325:85&#x2013;100. doi: 10.1007/978-3-540-77349-8_5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-540-77349-8_5</ArticleId><ArticleId IdType="pubmed">18637501</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeisel MB, Fofana I, Fafi-Kremer S, Baumert TF. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. J Hepatol. 2011;54(3):566&#x2013;576. doi: 10.1016/j.jhep.2010.10.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2010.10.014</ArticleId><ArticleId IdType="pubmed">21146244</ArticleId></ArticleIdList></Reference><Reference><Citation>Plotkin SA. Vaccines: past, present and future. Nat Med. 2005;11(4 Suppl):S5&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095920</ArticleId><ArticleId IdType="pubmed">15812490</ArticleId></ArticleIdList></Reference><Reference><Citation>Alaraj A, Wallace A, Tesoro E, Ruland S, Amin-Hanjani S, Charbel FT, Aletich V. Heparin induced thrombocytopenia: diagnosis and management. J Neurointerv Surg. 2010;2(4):371&#x2013;378. doi: 10.1136/jnis.2010.002840.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnis.2010.002840</ArticleId><ArticleId IdType="pubmed">21990651</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerda B, Ceron JJ, Tomas-Barberan FA, Espin JC. Repeated oral administration of high doses of the pomegranate ellagitannin punicalagin to rats for 37 days is not toxic. J Agric Food Chem. 2003;51(11):3493&#x2013;3501. doi: 10.1021/jf020842c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jf020842c</ArticleId><ArticleId IdType="pubmed">12744688</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang YN, Zhao DD, Gao B, Zhong K, Zhu RX, Zhang Y, Xie WJ, Jia LR, Gao H. Anti-hyperglycemic effect of chebulagic acid from the fruits of terminalia chebula retz. Int J Mol Sci. 2012;13(5):6320&#x2013;6333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3382786</ArticleId><ArticleId IdType="pubmed">22754367</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida T, Amakura Y, Yoshimura M. Structural features and biological properties of ellagitannins in some plant families of the order myrtales. Int J Mol Sci. 2010;11(1):79&#x2013;106. doi: 10.3390/ijms11010079.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms11010079</ArticleId><ArticleId IdType="pmc">PMC2820991</ArticleId><ArticleId IdType="pubmed">20162003</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin TC, Chien SC, Chen HF, Hsu FL. Tannins and related compounds from combretaceae plants. Chin Pharm J. 2000;52(1):1&#x2013;26. doi: 10.1211/0022357001773616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1211/0022357001773616</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin TC, Nonaka G, Nishioka I, Ho FC. Tannins and related compounds. CII. Structures of terchebulin, an ellagitannin having a novel tetraphenylcarboxylic acid (terchebulic acid) moiety, and biogenetically related tannins from Terminalia chebula Retz. Chem Pharm Bull. 1990;38:3004&#x2013;3008. doi: 10.1248/cpb.38.3004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/cpb.38.3004</ArticleId></ArticleIdList></Reference><Reference><Citation>Pouysegu L, Deffieux D, Malik G, Natangelo A, Quideau S. Synthesis of ellagitannin natural products. Nat Prod Rep. 2011;28(5):853&#x2013;874. doi: 10.1039/c0np00058b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/c0np00058b</ArticleId><ArticleId IdType="pubmed">21321753</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>